GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PYC Therapeutics Ltd (ASX:PYC) » Definitions » Retained Earnings

PYC Therapeutics (ASX:PYC) Retained Earnings : A$-133.26 Mil (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is PYC Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. PYC Therapeutics's retained earnings for the quarter that ended in Dec. 2023 was A$-133.26 Mil.

PYC Therapeutics's quarterly retained earnings declined from Dec. 2022 (A$-111.62 Mil) to Jun. 2023 (A$-118.17 Mil) and declined from Jun. 2023 (A$-118.17 Mil) to Dec. 2023 (A$-133.26 Mil).

PYC Therapeutics's annual retained earnings declined from Jun. 2021 (A$-81.52 Mil) to Jun. 2022 (A$-95.38 Mil) and declined from Jun. 2022 (A$-95.38 Mil) to Jun. 2023 (A$-118.17 Mil).


PYC Therapeutics Retained Earnings Historical Data

The historical data trend for PYC Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PYC Therapeutics Retained Earnings Chart

PYC Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.93 -63.75 -81.52 -95.38 -118.17

PYC Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87.94 -95.38 -111.62 -118.17 -133.26

PYC Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


PYC Therapeutics  (ASX:PYC) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


PYC Therapeutics (ASX:PYC) Business Description

Traded in Other Exchanges
N/A
Address
6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.

PYC Therapeutics (ASX:PYC) Headlines

No Headlines